490 related articles for article (PubMed ID: 31416571)
1. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.
Cervena K; Vodicka P; Vymetalkova V
Mutat Res Rev Mutat Res; 2019; 781():100-129. PubMed ID: 31416571
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.
Zeng H; He B; Yi C; Peng J
J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
Liu SC
World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and monitoring of virus-associated cancer using cell-free DNA.
Scholte LL; Bethony JM; Xian RR
Curr Opin Virol; 2023 Jun; 60():101331. PubMed ID: 37187125
[TBL] [Abstract][Full Text] [Related]
6. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
[TBL] [Abstract][Full Text] [Related]
7. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
[TBL] [Abstract][Full Text] [Related]
8. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?
Kahlert C
Cancer Res; 2019 May; 79(10):2462-2465. PubMed ID: 31043377
[TBL] [Abstract][Full Text] [Related]
9. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H; Wei W; Ye Z; Zheng J; Xu RH
Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
[TBL] [Abstract][Full Text] [Related]
10. Cell-Free DNA: Applications in Different Diseases.
Ranucci R
Methods Mol Biol; 2019; 1909():3-12. PubMed ID: 30580419
[TBL] [Abstract][Full Text] [Related]
11. Predicting tumour content of liquid biopsies from cell-free DNA.
Cardner M; Marass F; Gedvilaite E; Yang JL; Tsui DWY; Beerenwinkel N
BMC Bioinformatics; 2023 Sep; 24(1):368. PubMed ID: 37777714
[TBL] [Abstract][Full Text] [Related]
12. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
Ponti G; Manfredini M; Tomasi A
Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
[TBL] [Abstract][Full Text] [Related]
13. When Tissue Is the Issue: Expanding Cell-Free DNA "Liquid Biopsies" to Supernatants and Nonplasma Biofluids.
Paulson V; Konnick EQ; Lockwood CH
Clin Lab Med; 2022 Sep; 42(3):485-496. PubMed ID: 36150825
[TBL] [Abstract][Full Text] [Related]
14. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
15. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
[TBL] [Abstract][Full Text] [Related]
16. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics.
Song P; Wu LR; Yan YH; Zhang JX; Chu T; Kwong LN; Patel AA; Zhang DY
Nat Biomed Eng; 2022 Mar; 6(3):232-245. PubMed ID: 35102279
[TBL] [Abstract][Full Text] [Related]
17. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy.
Zeng C; Stroup EK; Zhang Z; Chiu BC; Zhang W
Cancer Commun (Lond); 2019 Mar; 39(1):12. PubMed ID: 30922396
[TBL] [Abstract][Full Text] [Related]
18. Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer.
Joosse SA; Pantel K
Cancer Res; 2022 Jun; 82(12):2213-2215. PubMed ID: 35702889
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy with cell free DNA: new horizons for prostate cancer.
Ponti G; Maccaferri M; Percesepe A; Tomasi A; Ozben T
Crit Rev Clin Lab Sci; 2021 Jan; 58(1):60-76. PubMed ID: 32805148
[TBL] [Abstract][Full Text] [Related]
20. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
